Kilitch Drugs Reaches 52-Week High Amidst Mixed Sector Performance and Growth Indicators
Kilitch Drugs (India) has reached a new 52-week high, reflecting significant growth over the past year, with net sales and profit showing impressive increases. Despite recent underperformance relative to its sector, the company maintains a bullish technical trend, although it faces challenges such as a low return on equity.
Kilitch Drugs (India) has made headlines today as its stock price reached a new 52-week high of Rs. 500.05, marking a significant milestone for the microcap pharmaceutical company. Despite this achievement, the stock has underperformed its sector by 3.65% today, following a trend reversal after three consecutive days of gains. The intraday trading saw a high of Rs. 500.05, while the stock dipped to a low of Rs. 471.85.In terms of performance metrics, Kilitch Drugs has shown impressive growth over the past year, with a remarkable 37.82% increase, significantly outpacing the Sensex's 8.20% growth. The company has consistently reported positive results, with net sales growing at an annual rate of 30.05% and operating profit soaring by 77.34%. The latest quarterly results revealed a net profit growth of 82.17%, with a PAT of Rs. 10.40 crore, reflecting a robust 113.2% increase compared to the previous four-quarter average.
Kilitch Drugs is currently trading above its moving averages, indicating a bullish technical trend. However, it is important to note that the company faces challenges, including a low return on equity of 7.27%. Overall, Kilitch Drugs (India) continues to demonstrate strong performance indicators, positioning itself favorably within the pharmaceuticals and biotechnology sector.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
